T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma

Jiachen Wang, Ke Shen, Wei Mu, Li Weigang, Meilan Zhang, Wei Zhang, Zhe Li, Tong Ge, Zhoujie Zhu, Shangkun Zhang, Caixia Chen, Shugang Xing, Li Zhu, Liting Chen, Na Wang, Liang Huang, Dengju Li, Min Xiao, Jianfeng ZhouFrontiers in Immunology 2022 · DOI

TL;DR

This study identifies T-cell intrinsic defects, specifically germline genetic variants in immune-related genes, as a significant factor contributing to primary resistance in diffuse large B-cell lymphoma (DLBCL) patients treated with CD19/CD22 CAR T-cell therapy. Understanding these genetic predispositions could pave the way for personalized treatment strategies and improved CAR T-cell efficacy.

What Problem Does This Paper Address?

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), offering remarkable efficacy. However, a substantial portion of patients either don't respond initially (primary resistance) or relapse after an initial response. While extrinsic factors like the tumor microenvironment are known contributors, the intrinsic T-cell defects that lead to this primary resistance remain poorly understood. This paper aims to elucidate these intrinsic T-cell dysfunctions by investigating the clinical and genetic characteristics of patients who exhibit T-cell defects after CAR T-cell therapy, seeking to identify factors that predict and explain this resistance.

Methods

The researchers conducted a retrospective analysis of 135 r/r DLBCL patients who received CD19/CD22 cocktail CAR T-cell therapy. They established two groups: a "T-normal" group (n=22) and a "T-defect" group (n=26), based on four key criteria: CAR T-cell expansion (Cmax), CAR T-cell persistence at 3 months (Tlast), B-cell recovery, and initial treatment response.

To identify risk factors for T-cell dysfunction, they employed univariate and multivariate regression analyses. Furthermore, they utilized whole-exome sequencing (WES) to analyze germline genetic variations in genes related to T-cell biology, immune regulation, and metabolism. Specific focus was placed on identifying germline variants enriched in the T-defect group compared to the T-normal group.

Datasets

The study utilized data from 135 patients with r/r DLBCL treated at Tongji Hospital between January 2019 and August 2020. This cohort was screened, and a subset of 48 patients meeting specific T-cell characteristic criteria were included for detailed analysis. The germline genetic data was generated through whole-exome sequencing of patient peripheral blood mononuclear cells (PBMCs).

Key Insights and Ideas

  • Germline Genetics as a Key Player: The most striking insight is the significant enrichment of germline variants in T-cell-related genes within the "T-defect" group. This suggests that pre-existing genetic predispositions, rather than solely acquired defects, can profoundly impact CAR T-cell function and treatment outcomes.
  • Beyond CAR Structure: The identified genetic variations weren't limited to CAR structure genes but spanned a broad spectrum of T-cell biology, including TCR signaling, immune regulation, cytokine/chemokine pathways, and metabolism. This highlights the complex interplay of factors that govern T-cell functionality.
  • Specific Gene Culprits: The study pinpointed UNC13D and CX3CR1 as particularly important genes. Heterozygous UNC13D mutations were highly enriched in the T-defect group, and compound heterozygous CX3CR1 variants, known to be pathogenic, were also significantly more prevalent. These findings offer concrete targets for further investigation.
  • LDH as a Biomarker: Elevated lactate dehydrogenase (LDH) levels before leukapheresis emerged as an independent risk factor for T-cell dysfunction. This provides a readily accessible clinical marker that could help stratify patients at higher risk of poor CAR T-cell response.
  • Low CRS, High Risk: Conversely, a lower grade of cytokine release syndrome (CRS) after CAR T-cell infusion was associated with T-cell dysfunction. This counterintuitive finding suggests that a milder inflammatory response might indicate a less robust CAR T-cell activation and, consequently, a higher risk of resistance.

Key Results

  • T-cell dysfunction is linked to specific germline variants: 96% of patients in the T-defect group harbored germline variants in 47 T-cell-related genes, compared to only 41% in the T-normal group (p<0.0001).
  • UNC13D mutations are highly prevalent in T-defect patients: 26.9% of T-defect patients had heterozygous UNC13D mutations, versus 0% in the T-normal group (p=0.008).
  • CX3CR1 variants are enriched in T-defect patients: 3 out of 26 T-defect patients carried compound heterozygous CX3CR1 variants, which are associated with pathogenic effects.
  • LDH and CRS as independent risk factors: Higher LDH levels before leukapheresis (HR=1.922, p=0.045) and lower CRS grade (HR=0.150, p=0.026) were identified as independent risk factors for T-cell dysfunction.
  • CAR T-cell expansion and persistence are reduced in T-defect patients: Cmax and Tlast were significantly lower in the T-defect group (p<0.0001).
  • B-cell recovery and response rates differ: B-cell recovery within 3 months was higher (37.5% vs. 0%, p=0.002) and initial response rates were lower (33.3% vs. 100%, p<0.0001) in the T-defect group.

Limitations and Future Work

The authors acknowledge the limitations of their study, including its retrospective nature and the single-center design, which limits the generalizability of the findings. They also note the relatively small sample size.

Future work should focus on:

  • Multicenter validation: Conducting larger, multicenter studies to validate these findings and confirm the identified risk factors.
  • Exploring PID diversity: Investigating germline genetic variations across diverse populations to account for potential ethnic differences in primary immunodeficiencies (PIDs).
  • Functional validation: Further experimental validation of the identified germline variants (e.g., UNC13D, CX3CR1) in functional assays to fully elucidate their impact on CAR T-cell behavior.
  • Developing novel strategies: Using these insights to develop personalized CAR T-cell therapies, potentially including screening for germline mutations and considering allogeneic or universal CAR-T products for patients with identified T-cell defects.
  • Understanding CRS mechanisms: Further research is needed to understand the complex relationship between CRS severity and T-cell dysfunction in the context of CAR T-cell therapy.

Summary updated

Abstract

Despite impressive progress, a significant portion of patients still experience primary or secondary resistance to chimeric antigen receptor (CAR) T-cell immunotherapy for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). The mechanism of primary resistance involves T-cell extrinsic and intrinsic dysfunction. In the present study, a total of 135 patients of DLBCL treated with murine CD19/CD22 cocktail CAR T-therapy were assessed retrospectively. Based on four criteria (maximal expansion of the transgene/CAR-positive T-cell levels post-infusion [C<sub>max</sub>], initial persistence of the transgene by the CAR transgene level at +3 months [T<sub>last</sub>], CD19+ B-cell levels [B-cell recovery], and the initial response to CAR T-cell therapy), 48 patients were included in the research and divided into two groups (a T-normal group [n=22] and a T-defect [n=26] group). According to univariate and multivariate regression analyses, higher lactate dehydrogenase (LDH) levels before leukapheresis (hazard ratio (HR) = 1.922; <i>p</i> = 0.045) and lower cytokine release syndrome (CRS) grade after CAR T-cell infusion (HR = 0.150; <i>p</i> = 0.026) were independent risk factors of T-cell dysfunction. Moreover, using whole-exon sequencing, we found that germline variants in 47 genes were significantly enriched in the T-defect group compared to the T-normal group (96% vs. 41%; p<0.0001), these genes consisted of CAR structure genes (n=3), T-cell signal 1 to signal 3 genes (n=13), T cell immune regulation- and checkpoint-related genes (n=9), cytokine- and chemokine-related genes (n=13), and T-cell metabolism-related genes (n=9). Heterozygous germline <i>UNC13D</i> mutations had the highest intergroup differences (26.9% vs. 0%; <i>p</i>=0.008). Compound heterozygous <i>CX3CR1</i><sup>I249/M280</sup> variants, referred to as pathogenic and risk factors according to the ClinVar database, were enriched in the T-defect group (3 of 26). In summary, the clinical characteristics and T-cell immunodeficiency genetic features may help explain the underlying mechanism of treatment primary resistance and provide novel insights into CAR T-cell immunotherapy.
BibTeX
@inproceedings{wang2022t,
  author = {Jiachen Wang and Ke Shen and Wei Mu and Li Weigang and Meilan Zhang and Wei Zhang and Zhe Li and Tong Ge and Zhoujie Zhu and Shangkun Zhang and Caixia Chen and Shugang Xing and Li Zhu and Liting Chen and Na Wang and Liang Huang and Dengju Li and Min Xiao and Jianfeng Zhou},
  title = {{T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.873789},
}
Figure